Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Peng Zhang
Institution:
Shanghai Institute of Pharmaceutical Industry
Observed institutions:
Fudan University,
Shanghai Institute of Pharmaceutical Industry
ORCID:
0000-0002-2703-6009
Observed ORCID:
0000-0002-2703-6009
OpenAlex ID:
A5082197347
Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia
2021
·
Peng Zhang
, Zhihui Min
, et al.
·
Journal of Medicinal Chemistry
·
23
Design, synthesis and identification of N, N-dibenzylcinnamamide (DBC) derivatives as novel ligands for α-synuclein fibrils by SPR evaluation system
2020
·
Yan-Fei Chen
, Jiang Bian
, et al.
·
Bioorganic & Medicinal Chemistry
·
16
Discovery of imidazo[1,2-b]pyridazine macrocyclic derivatives as novel ALK inhibitors capable of combating multiple resistant mutants
2023
·
Xiaofei Xiao
, Yunsheng Xu
, et al.
·
Bioorganic & Medicinal Chemistry Letters
·
8
Design, synthesis and evaluate of indazolylaminoquinazoline derivatives as potent Tropomyosin receptor kinase (TRK) inhibitors
2024
·
Yunsheng Xu
, Wei Zhao
, et al.
·
Bioorganic & Medicinal Chemistry
·
5
Scaffold hopping for discovery of N, N-dibenzylcinnamamide (DBCA) derivatives as novel allosteric GSK-3β inhibitors: Design, synthesis and anti-inflammatory evaluation
2024
·
Xinyi Zhang
, Weiwei Zhao
, et al.
·
Results in Chemistry
·
1
Discovery of novel diarylurea derivatives as potent type II TRK inhibitors for combating multiple acquired resistant mutants
2025
·
Wei Zhao
, Zhenghai Wang
, et al.
·
Bioorganic Chemistry
Show more works
View as search
Works count:
6
Citation count:
53
H-index:
4
I10-index:
2
Year
Topic
Type